pages:
-
Age-Related Macular Degeneration: The Effect of Training on Visual Performance and Neural Activity
-
Agile and Fused Vehicle Dynamics for Open Architecture and Cyber-Physics System Design
-
Agile Tire Mobility for Severe Terrain and Cyber-Threat Environments
-
Aging and ARM: Dark Adaptation Impairment
-
Aging and Somatotropic Axis and Abeta Toxicity
-
Aging in Puerto Rico: Longitudinal Follow-Up of the PREHCO Study
-
Aging Well with COPD through Geriatrics-Palliative Care
-
Agonism of DR3 for Enhanced Treg Cell Function in IBD
-
Agreement Between ADPH & Bd of Trustees of the Univ of AL for the Univ of AL "TB Contract"
-
Agreement Between ADPH & Bd of Trustees of the Univ of AL for the Univ of AL "TB Contract"
-
Agreement Between ADPH & The Board of Trustees of the University of AL for the University of Alabama at Birmingham "TB Contract"
-
Agreement Between the ADPH and Board of Trustees of the Univ of AL for the Univ of AL at B'ham "TB Contract"
-
Agreement Between the ADPH and Board of Trustees of the Univ of AL for the Univ of AL at B'ham "TB Contract"
-
Agreement Between The ADPH and The Board of Trustees of the Univ of AL for the Univ of AL at B'ham
-
AHA-Data Grant Fellowship
-
AHEC Point of Service Maint & Enhancement
-
AHEC Point of Service Maint & Enhancement
-
AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
-
AHOD1331-A Randomized Phase III Study of Brentuximab Vedotin for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma in Children and Adolescents
-
AHOD1721, Risk-based, Response-Adapted, Phase ll Open- Label Trail of Nivolumab+Brentuximab Vedotin(N+Bv) for Children,Adolescents, and Young Adults with Relapsed/ Refractory (R/R) CD30+ Classic Hodgkin Lymphoma (cHL) after Failure of First -Line Therapy, followed by Brentuximab+Bendamustine(Bv+B) for participants with a suboptimal response;CheckMate 744:Checkpoint Pathway and Nivolumab Clinical Trail Evaluation.
-
AHOD1822 -- AnOpen-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)
-
AHRQ ECHO National Nursing Home COVID-19 Action Network
-
AI4CHRON - An Accessible and Inclusive Artificial Intelligence Assisted Chronic Disease Self-Management Telehealth Platform
-
AIACC Needs Assessment
-
AIDS Clinical Trial Group (ACTG 5324) -- A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
-
Aids Clinical Trial Group: ACTG
-
AIDS Clinical Trials Group (ACTG)
-
Aids Clinical Trials Group (ACTG) - TSG/Research Science Committee
-
AIDS Clinical Trials Group (ACTG) A5332/A5340 Salary Support
-
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections [ACTG LOC: PF Chair A5332]
pages:
